IFNB1 and myeloid sarcoma: The aim of this study was to use highly specific serological assays to measure serum IgG reactivity to EBVgp350 and MeV NCORE in patients with MS and healthy controls and to determine if serum IgG reactivity changes in patients treated with IFNβ and/or NAT.